

# Huan-Chang J. Liang, PhD

Stellar-Chance Labs, 422 Curie Boulevard, Philadelphia PA, 19104 • [huan-chang.liang@penntmedicine.upenn.edu](mailto:huan-chang.liang@penntmedicine.upenn.edu)

## EDUCATION

- **PhD in Molecular Signal Transduction**, Medical University of Vienna 2016–2020
- **MRes & DIC in Cancer Biology**, Imperial College London 2013–2014
- **BSc in Life Science**, National Taiwan Normal University 2008–2012

## TRAINING AND PROFESSIONAL EXPERIENCE

- **Postdoctoral Researcher**, University of Pennsylvania, Pathology and Laboratory Medicine 2020–present
- **Visiting Scholar**, Roche Diagnostics, Foundation Medicine 07/2019
- **Visiting Scholar**, Charité – Universitätsmedizin Berlin 06/2018–09/2018
- **Early Stage Researcher**, Medical University of Vienna, Clinical Institute of Pathology 2016–2020
- **Research Assistant**, Imperial College London, Comprehensive Cancer Imaging Centre 2014–2016

## AWARDS AND FELLOWSHIPS

- Lymphoma Research Foundation – Postdoctoral Fellowship Grants: “Oncogenic role of NPM1-TYK2 in T-cell lymphoma.” Award ID: 889995. US. Period: 2022–2024.
- Marie Skłodowska-Curie Innovative Training Networks – European Training Networks (MSCA-ITN-ETN) Fellowship. Grant Agreement No. 675712. EU. Period: 2016–2019.
- National Science Council – College Student Research Fellowship: “RNAi-mediated p53 inhibition downregulates Ellipticine-induced nuclear cotranslocalisation of p53 and AKT in lung epithelial cancer.” Award ID: 100-2815-C-003-047-B. Taiwan. Period: 2011–2012.
- 6<sup>th</sup> Novartis Award of the German Society for Pathology – 105<sup>th</sup> Annual Meeting of the German Society for Pathology, 2022.
- European Association for Cancer Research (EACR) Poster Prize – 8<sup>th</sup> Annual Meeting of the European Research Initiative on ALK-Related Malignancies, 2017.
- Best Poster Prize – 2017 Autumn Conference of Austrian Society of Pathology, 2017.

## PUBLICATIONS

- **Refereed Papers (Journal Articles):** <https://scholar.google.com/citations?user=CznVu6UAAAAJ&hl=en>
- **Conference Papers (Abstracts):**
  - **Liang HC**, *et al.* The AP-1 –BATF and –BATF3 module: divergent roles in tumour growth, invasion and angiogenesis in anaplastic large cell lymphoma. *Brit J Haematol.* 2018; 182 (S1): 43. doi: 10.1111/bjh.15536\_000\_050.
  - **Liang HC**, *et al.* The AP-1 –BATF and –BATF3 module is essential for growth and survival of anaplastic large cell lymphoma. *Der Pathologe.* 2017; 38: 483. doi: 10.1007/s00292-017-0326-5.
  - Maginn EN, de Sousa CH, Astuti Y, **Liang HC**, *et al.* DNA-PKcs and regulators of ubiquitinylation are key therapeutic targets for chemotherapy resistant ovarian and pancreatic cancers, and modulate activity of the homologous repair pathway. Mammalian DNA Repair Gordon Research Seminar, California, USA, 2015.
  - Wang JP, Yu YC, **Liang HC**, *et al.* Nuclear translocation of phosphorylated AKT-Ser<sup>473</sup> is critical for Ellipticine-induced apoptosis in A549 lung epithelial cancer cells. The 27<sup>th</sup> Joint Annual Conference of Biomedical Science, Taipei, Taiwan, 2012.